id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-296259-4kdblf4z	Oudit, Gavin Y	Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19	2020-05-14		.txt	text/plain	1811	102	44	This editorial refers to 'Circulating plasma concentrations of ACE2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors' † , by I.E. Sama et al., on page 1810. Angiotensin-converting enzyme 2 (ACE2) has emerged as the negative regulator of the renin-angiotensin system (RAS) and was more recently identified as the SARS-CoV-2 receptor responsible for the current COVID-19 pandemic. [3] [4] [5] Direct clinical evidence came from SARS and the current COVID-19 pandemic, where there is down-regulation of tissue ACE2 through endocytosis and proteolytic processing which leads to a corresponding increase in plasma angiotensin II (Ang II) levels as seen in COVID-19 patients (linearly correlated with SARS-CoV-2 viral load), thus providing a direct link between the tissue and systemic RAS. obtained in heart failure patients in the pre-COVID-19 period offer supporting evidence to continue ACE inhibitors or ARBs in patients at risk for SARS-CoV-2 infection.	./cache/cord-296259-4kdblf4z.txt	./txt/cord-296259-4kdblf4z.txt